Evidence map›Paper›PMID 37854152›Full record

ArticleTranslational lung cancer research2023

Are radiomic signatures ready for incorporation in the clinical pipeline?

Apurva Singh, Leonid Roshkovan, Jeffrey C Thompson, Despina Kontos, Sharyn I Katz

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Apurva SinghDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
Leonid RoshkovanDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
Jeffrey C ThompsonDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Thoracic Oncology Group, University of Pennsylvania, Philadelphia, PA, USA.
Despina KontosDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
Sharyn I KatzDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.

Funding

Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC)on ImmunotherapyR01CA264835 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KATZ, SHARYN, KONTOS, DESPINA · 2021 to 2025
$2.8M
A multimodal approach to develop molecular markers to predict response to immune targeted agents in non-small cell lung cancerK08CA234335 · NCI · UNIVERSITY OF PENNSYLVANIA · PI THOMPSON, JEFFREY C · 2018 to 2022
$982k
NCI NIH HHS K08 CA234335NCI NIH HHS R01 CA264835
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

precision medicineRadiomicstumor heterogeneity

Identifiers

PMID37854152
PMCPMC10579831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.